PMID- 23990051
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20211021
IS  - 1591-9528 (Electronic)
IS  - 1591-8890 (Linking)
VI  - 14
IP  - 4
DP  - 2014 Nov
TI  - Evaluation of the Abelson gene as a control gene for real-time quantitative PCR 
      in multiple myeloma.
PG  - 457-60
LID - 10.1007/s10238-013-0257-2 [doi]
AB  - The Abelson (ABL) gene was the best control gene for quantitative PCR 
      (qPCR)-based diagnosis and minimal residual disease detection in leukemic 
      patients. However, there is still no concerted effort focused on the optimization 
      of control genes in multiple myeloma (MM). The results of this study will provide 
      a basis for the use of ABL as a control gene for the quantification of aberrantly 
      expressed genes in MM. We analyzed ABL, glyceraldehyde-3-phosphate dehydrogenase 
      (GAPDH), beta-glucuronidase, and beta2-microglobulin genes expression in bone marrow 
      samples of 62 MM patients and 31 healthy donors. MAGE-C1, the most commonly 
      expressed cancer-testis antigen gene in MM, which is to be a potential clinical 
      indicator for auxiliary diagnosis and prognostic evaluation in MM, was also 
      detected. Our experimental results show that the copy numbers of the four control 
      genes were well correlated in all samples detected. The quantitative data for 
      MAGE-C1 using the four control genes also had high correlations. ABL and GAPDH 
      genes were stably expressed in healthy donors and MM patients during therapy and 
      did not vary with disease state. ABL is stable in the MM bone marrow mononuclear 
      fraction, and it could be used as a reliable control gene for the normalization 
      of qPCR studies in MM.
FAU - Zhang, Yao
AU  - Zhang Y
AD  - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Institute of 
      Hematology, Peking University People's Hospital, 11 Xi-Zhi-Men South Street, 
      Beijing, 100044, China.
FAU - Ruan, Guo-Rui
AU  - Ruan GR
LA  - eng
PT  - Evaluation Study
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20130830
PL  - Italy
TA  - Clin Exp Med
JT  - Clinical and experimental medicine
JID - 100973405
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (MAGEC1 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (beta 2-Microglobulin)
RN  - EC 1.2.1.- (Glyceraldehyde-3-Phosphate Dehydrogenases)
RN  - EC 3.2.1.31 (Glucuronidase)
SB  - IM
MH  - Antigens, Neoplasm/genetics
MH  - Bone Marrow/pathology
MH  - Gene Expression Profiling
MH  - *Genes, abl
MH  - Glucuronidase/genetics
MH  - Glyceraldehyde-3-Phosphate Dehydrogenases/genetics
MH  - Humans
MH  - Multiple Myeloma/*diagnosis/*genetics
MH  - Neoplasm Proteins/genetics
MH  - Real-Time Polymerase Chain Reaction/*methods/*standards
MH  - Reference Standards
MH  - beta 2-Microglobulin/genetics
EDAT- 2013/08/31 06:00
MHDA- 2015/06/24 06:00
CRDT- 2013/08/31 06:00
PHST- 2013/05/30 00:00 [received]
PHST- 2013/08/20 00:00 [accepted]
PHST- 2013/08/31 06:00 [entrez]
PHST- 2013/08/31 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - 10.1007/s10238-013-0257-2 [doi]
PST - ppublish
SO  - Clin Exp Med. 2014 Nov;14(4):457-60. doi: 10.1007/s10238-013-0257-2. Epub 2013 
      Aug 30.